IL17A and achondroplasia: A notable difference in cytokine expression has been observed between those affecting the nail bed and those impacting skin lesions, explaining the suboptimal response to IL-17A inhibitors but improvement in erythema and pustules in ACH patients with severe nail damage, who responded well after switching to adalimumab treatment (6).